Fibrinogen from rat plasma
SIGMA/F6755 - 60-80% protein (≥60% of protein is clottable)
Synonym: Factor I
CAS Number: 9001-32-5
EC Number: 232-598-6
MDL Number: MFCD00131060
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F6755-100MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F6755-25MG
| biological source | rat plasma |
| concentration | 60-80% (biuret) |
| form | powder |
| mol wt | α-chain 63.5 kDa |
| β-chain 56 kDa | |
| γ chain 47 kDa (about 4% carbohydrate content) | |
| soluble dimer 340 kDa | |
| quality | 60-80% protein (≥60% of protein is clottable) |
| Quality Level | 200  |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| immunoblotting: suitable | |
| UniProt accession no. | P02680  |
| P06399 |
|
| P14480 |
| Analysis Note: | Contains ~12% sodium citrate and ~18% sodium chloride. |
| Analysis Note: | Protein determined by biuret. |
| Application: | Fibrinogen from rat plasma has been used: • in the preparation of growth factor solutions • to apply on discontinuous SDS-polyacrylamide gels for the detection of IgG (immunoglobulins) type antibodies by immunoblot analysis • to mix with cell suspension to form a clot and retain the cells for avoiding its dispersion during transplantation |
| Application: | Fibrinogen has been used in studies of haemostatic therapy in surgical and massive trauma patients. These studies have shown that fibrinogen may prove to be more superior in stopping blood loss when compared to using fresh frozen plasma (FFP). |
| Biochem/physiol Actions: | Acute phase protein that is part of the coagulation cascade of proteins. |
| Biochem/physiol Actions: | Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |